Tel Aviv Study Shows Ketamine Relieves Pain Without Dissociative 'Trip' Experience
A groundbreaking study led by the Psychedelic Research Center at Tel Aviv University in collaboration with Ichilov Hospital has demonstrated that ketamine can alleviate pain without inducing the intense dissociative experience traditionally thought necessary for its therapeutic effect. The research, published in Neuropsychopharmacology, involved 37 healthy volunteers who received ketamine and placebo infusions in separate sessions while undergoing functional MRI scans and controlled pain stimuli.
Participants reported both pain intensity and dissociation levels in real time. Results showed that although ketamine reduced pain and increased dissociation, there was no correlation between the two. Brain imaging revealed that pain relief corresponded with decreased activity in brain regions processing pain and suffering, whereas dissociation was linked to changes in the brain's default mode network responsible for self-awareness and memory. This indicates two distinct neural mechanisms underlie ketamine's effects.
Prof. Talma Hendler, head of the Psychedelic Research Center, explained that this separation suggests ketamine's pain-relieving properties can be harnessed without the subjective "trip" experience. However, the findings do not necessarily apply to other psychedelics like psilocybin or MDMA, which act on different brain receptors and may require the subjective experience for therapeutic benefit.
The study has significant implications for pharmaceutical development, as companies are already working on "clean ketamine" molecules designed to block pain without causing dissociation. One such drug, Ketamir-2, has passed initial safety trials and aims to treat severe neuropathic pain without psychoactive side effects. Experts caution that despite these advances, ketamine treatment still requires medical supervision due to potential side effects and addiction risks.
While the prospect of ketamine treatments without dissociative effects could make therapy safer and more accessible, especially in emergency and psychiatric settings, researchers emphasize that home use remains premature. Current ketamine administration demands specialist oversight to manage safety and efficacy.
